Future Treatments in Ovarian Cancer
An expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.
Toxicities With PARP Inhibitors for Ovarian Cancer
Lyndsay Willmott, MD, explains the tolerability of PARP inhibitors for ovarian cancer and how to discuss dose reductions with patients.
Rucaparib Maintenance Therapy in Ovarian Cancer: The ARIEL3 Trial
A key opinion leader shares data from a phase III, ARIEL3, clinical trial on rucaparib maintenance treatment for ovarian cancer.
First-Line Therapies in Ovarian Cancer
Dr. Lyndsay Willmott discusses the front-line therapy options for ovarian cancer and the factors considered in choosing maintenance therapies.
Molecular Testing: Ovarian Cancer
An oncologist explains the importance of molecular testing in ovarian cancer and the implications of testing on treatment selection.
Case Presentation: A 57-Year-Old Woman With Ovarian Cancer
Lyndsay Willmott, MD, presents the case of a 57-year-old woman with ovarian cancer.